Patents by Inventor Gregory D. Lundquist

Gregory D. Lundquist has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oxime substituted imidazoquinolines
    Patent number: 7897767
    Abstract: Imidazo ring compounds (e.g., imidazoquinolines, 6,7,8,9-tetrahydroimidazoquinolines, imidazonaphthyridines, and imidazopyridines) with an oxime substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: March 1, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Tushar A. Kshirsagar, Gregory D. Lundquist, David T. Amos, Joseph F. Dellaria, Jr., Bernhard M. Zimmermann, Philip D. Heppner
  • OXIME SUBSTITUTED IMIDAZOQUINOLINES
    Publication number: 20090042925
    Abstract: Imidazo ring compounds (e.g., imidazoquinolines, 6,7,8,9-tetrahydroimidazoquinolines, imidazonaphthyridines, and imidazopyridines) with an oxime substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.
    Type: Application
    Filed: November 12, 2004
    Publication date: February 12, 2009
    Inventors: Tushar A. Kshirsagar, Gregory D. Lundquist, David T. Amos, Joseph F. Dellaria, JR., Bernhard M. Zimmermann, Philip D. Heppner
  • Piperazine derivatives
    Patent number: 7098212
    Abstract: The present invention relates to compounds of the formula I and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R1, R2, R3, R4 and R5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.
    Type: Grant
    Filed: October 18, 2002
    Date of Patent: August 29, 2006
    Inventors: Laura C. Blumberg, Matthew F. Brown, Matthew M. Hayward, Gregory D. Lundquist, Christopher S. Poss, Andrei Shavnya
  • Methods of using piperazine derivatives
    Publication number: 20040092529
    Abstract: The present invention relates to compounds of the formula I 1
    Type: Application
    Filed: October 16, 2003
    Publication date: May 13, 2004
    Applicant: Pfizer Inc
    Inventors: Laura C. Blumberg, Matthew F. Brown, Anderson S. Gaweco, Ronald P. Gladue, Matthew M. Hayward, Gregory D. Lundquist, Christopher S. Poss, Andrei Shavnya
  • Novel piperazine derivatives
    Publication number: 20040034034
    Abstract: The present invention relates to compounds of the formula I 1
    Type: Application
    Filed: October 18, 2002
    Publication date: February 19, 2004
    Inventors: Laura C. Blumberg, Matthew F. Brown, Matthew M. Hayward, Gregory D. Lundquist, Christopher S. Poss, Andrei Shavnya